Vivesto (VIVE.ST) Stock Analysis & AI Equity Report
Vivesto (VIVE.ST) overview
Vivesto (VIVE.ST) stock analysis and AI equity research. For the latest completed financial year, 2025, Vivesto reported revenue of SEK 0m and operating profit of SEK -34.4m; the year-end share price was 11.75 SEK and market capitalisation was SEK 7,264m. Vivesto is covered by Valuatum but does not yet have a published AI equity report. Generate a fresh report to get Vivesto's valuation, segment value analysis, reverse valuation, financial forecasts, key ratios, risks and catalysts.
Key metrics & valuation multiples
Figures updated on 2026-07-27. Data will be refreshed during report generation.
About Vivesto
Vivesto AB is a Swedish drug development company focused on oncology. Its portfolio includes Cantrixil, in development for blood cancer, and Paccal Vet, a veterinary oncology program being studied in dogs and cats. The company also retains Apealea, a paclitaxel-based product out-licensed for parts of Asia, while concentrating resources on its lead programs.
Generate the Vivesto report
Vivesto is on Valuatum's coverage list, but a full AI equity report hasn't been generated yet. Order one now for the complete company value map, reverse valuation, risk & catalyst analysis, and financial statements and estimates — plus a downloadable PDF.
Sources & methodology
Financial figures are sourced from Valuatum's financial model for Vivesto and represent the latest completed financial year (2025). See the methodology for the full Valuatum AI equity research framework.
Disclaimer: This is an AI-generated research material for informational purposes only. It is not investment advice or a buy/sell recommendation. Always perform your own analysis. Valuatum Oy, Helsinki, Finland.